Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Tamil Nadu: Cabinet approves land allocation for vaccine plant

      Tamil Nadu: Cabinet approves land allocation for vaccine plant

      Farhat Nasim16 Feb 2019 9:15 AM IST
      The project entails production of viral vaccines such as TCA anti-measles vaccine, Japanese encephalitis and anti-sera at the PII, Coonoor. Land for...
      Fortis appoints Vivek Kumar Goyal as Chief Financial Officer

      Fortis appoints Vivek Kumar Goyal as Chief Financial Officer

      Farhat Nasim15 Feb 2019 9:35 AM IST
      The Fortis board has approved his appointment as Chief Financial Officer. Vivek Kumar Goyal will be responsible for driving the entire gamut of the...
      Lupin gets FDA nod for Fluoxetine to treat depressive disorders

      Lupin gets FDA nod for Fluoxetine to treat depressive disorders

      Farhat Nasim15 Feb 2019 9:30 AM IST
      Lupin's Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen's Fluoxetine Tablets, 60mg. Fluoxetine 60 mg Hard Capsules are used to treat...
      Zydus receives USFDA approval for hypertension drug combo Triamterene, Hydrochlorothiazide Capsules

      Zydus receives USFDA approval for hypertension drug combo Triamterene, Hydrochlorothiazide Capsules

      Farhat Nasim14 Feb 2019 9:45 AM IST
      The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who have...
      Dr Reddys shares plunge nearly six percent after 11 observations by USFDA

      Dr Reddys shares plunge nearly six percent after 11 observations by USFDA

      Farhat Nasim14 Feb 2019 9:30 AM IST
      The company's shares tumbled 5.60 per cent to close at Rs 2,616.95 on BSE. During the day, it tanked 7.81 per cent to Rs 2,555.55.New Delhi: Hyderabad...
      Mylan launches Advair generic at 70 percent discount in US

      Mylan launches Advair generic at 70 percent discount in US

      Farhat Nasim14 Feb 2019 9:15 AM IST
      The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said.U.S: Mylan NV...
      Ahead of SC hearing, IMA protests against Oxytocin Ban

      Ahead of SC hearing, IMA protests against Oxytocin Ban

      Farhat Nasim13 Feb 2019 4:03 PM IST
      New Delhi: With the centre challenging the Delhi HC order setting aside the Centre's ban of manufacture and sale of oxytocin, the Indian Medical...
      Dr Reddys launches Tadalafil tablets for treating erectile dysfunction

      Dr Reddys launches Tadalafil tablets for treating erectile dysfunction

      Farhat Nasim13 Feb 2019 12:31 PM IST
      New Delhi: Hyderabad based drug major, Dr Reddy's has recently launched Tadalafil tablets in the US market. The drug launched is used to treat...
      Merck, Pfizer combo treatment improves kidney cancer survival

      Merck, Pfizer combo treatment improves kidney cancer survival

      Farhat Nasim13 Feb 2019 9:05 AM IST
      Approval of the combination to treat patients with RCC would put Merck again in competition with rival Bristol-Myers Squibb Co's Opdivo, which is...
      Sanofi, Regeneron slashes price of cholesterol drug by 60 percent

      Sanofi, Regeneron slashes price of cholesterol drug by 60 percent

      Farhat Nasim12 Feb 2019 9:05 AM IST
      Sanofi and Regeneron will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 per cent, as the drugmakers...
      Pfizer Japan recalls high BP drug over cancer-causing impurity

      Pfizer Japan recalls high BP drug over cancer-causing impurity

      Farhat Nasim11 Feb 2019 3:47 PM IST
      TOKYO - The Japanese subsidiary of Pfizer Inc is recalling a drug for high BP ( blood pressure) which was found to contain a carcinogenic substance in...
      Lupin gets USFDA nod to Tadalafil to treat pulmonary arterial hypertension

      Lupin gets USFDA nod to Tadalafil to treat pulmonary arterial hypertension

      Farhat Nasim10 Feb 2019 9:45 AM IST
      Tadalafil is also used to treat the symptoms of two conditions found in men: benign prostatic hyperplasia (BPH) and erectile dysfunction(ED)....
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok